Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CKPT Stock Forecast 2026-2027
$4.26
Current Price
$370.71M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CKPT Price Targets
+12.7%
To High Target of $4.80
+4.5%
To Median Target of $4.45
-3.8%
To Low Target of $4.10
CKPT Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
0.0%
1 Year Change
0.0%
Year-to-Date Change
-5.3%
From 52W High of $4.50
+136.7%
From 52W Low of $1.80
📊 TOP ANALYST CALLS
Did CKPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Checkpoint is one of their latest high-conviction picks.
Latest CKPT Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, CKPT has a neutral consensus with a median price target of $4.45 (ranging from $4.10 to $4.80). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $4.26, the median forecast implies a 4.5% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 12.7% upside. Conversely, the most conservative target is provided by Joseph Pantginis at HC Wainwright & Co., suggesting a 3.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CKPT Analyst Ratings
1
Buy
1
Hold
0
Sell
CKPT Price Target Range
Low
$4.10
Average
$4.45
High
$4.80
Current: $4.26
Latest CKPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CKPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $4.80 |
| Mar 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Neutral | Downgrade | $4.10 |
| Mar 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $4.80 |
| Mar 10, 2025 | Lake Street | Thomas Flaten | Hold | Downgrade | $4.10 |
| Jan 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $9.00 |
| Dec 16, 2024 | Lake Street | Thomas Flaten | Buy | Maintains | $7.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $20.00 |
| Jul 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $34.00 |
| Jun 24, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $34.00 |
| May 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $34.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $34.00 |
| Dec 20, 2023 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $4.00 |
| Dec 19, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $34.00 |
| Aug 16, 2023 | Lake Street | Thomas Flaten | Buy | Maintains | $14.00 |
| Aug 15, 2023 | Ladenburg Thalmann | Jeffrey Cohen | Buy | Maintains | $47.00 |
| Aug 15, 2023 | Cantor Fitzgerald | Jennifer Kim | Overweight | Maintains | $14.00 |
Checkpoint Therapeutics Inc. (CKPT) Competitors
The following stocks are similar to Checkpoint based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Checkpoint Therapeutics Inc. (CKPT) Financial Data
Checkpoint Therapeutics Inc. has a market capitalization of $370.71M with a P/E ratio of -3.0x. The company generates $41,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -137,500.0% and return on equity of -1,869.5%.
Valuation Metrics
Market Cap
$370.71M
Enterprise Value
$323.79M
P/E Ratio
-3.0x
PEG Ratio
-23.7x
Price/Sales
9,041.6x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-137,500.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.2%
Current Ratio
1.9x
Debt/Equity
0.0x
ROE
-1,869.5%
ROA
-152.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Checkpoint Therapeutics Inc. (CKPT) Business Model
About Checkpoint Therapeutics Inc.
What They Do
Develops innovative cancer treatments using immunotherapy.
Business Model
The company generates revenue by developing and commercializing novel cancer therapies that enhance the body's immune response to tumors. Their focus on a diverse pipeline of antibody-based and small molecule therapeutics positions them to address unmet medical needs in oncology, thereby attracting investment for clinical trials and product development.
Additional Information
Checkpoint Therapeutics is actively involved in rigorous clinical trials to validate the safety and efficacy of its treatments, which is crucial for gaining regulatory approval. The company operates at the intersection of biotechnology and healthcare, appealing to investors seeking opportunities in cutting-edge medical advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
24
CEO
Mr. James F. Oliviero III, C.F.A.
Country
United States
IPO Year
2016
Website
checkpointtx.comCheckpoint Therapeutics Inc. (CKPT) Latest News & Analysis
Latest News
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
1 year ago
Quick Summary
UNLOXCYT™ (cosibelimab-ipdl) received FDA approval in December 2024 as the first anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma.
Why It Matters
The FDA approval of UNLOXCYT™ positions the company as a leader in treating advanced skin cancer, potentially boosting revenue and stock value significantly.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Checkpoint Therapeutics, Inc. plans to be sold to Sun Pharmaceutical Industries for $4.10 per share, plus a contingent value right of up to $0.70 per share. An investigation is underway.
Why It Matters
The investigation into Checkpoint Therapeutics' sale could affect the transaction's completion and share value, impacting investor confidence and potential returns.
Source: Business Wire
Market Sentiment:
Neutral
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
1 year ago
Quick Summary
UNLOXCYT™ (cosibelimab-ipdl) received FDA approval as the first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, representing a significant advancement in cancer therapy.
Why It Matters
FDA approval of UNLOXCYT™ positions the company as a market leader in treating advanced cutaneous squamous cell carcinoma, potentially boosting revenue and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kaskela Law LLC is investigating the fairness of the buyout of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) for its shareholders, announced on March 13, 2025.
Why It Matters
The investigation into Checkpoint's buyout raises concerns about the fairness of the deal, potentially impacting shareholder value and market confidence in the acquisition.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Checkpoint Therapeutics (CKPT) shares surged over 60% after Sun Pharmaceutical Industries announced its acquisition for $4.10 per share, totaling up to $355 million in cash.
Why It Matters
Checkpoint Therapeutics’ acquisition by Sun Pharma at $4.10 per share boosts investor confidence, indicating strong market interest and potential for future growth in the biotech sector.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for potential fiduciary duty breaches related to its transaction with Sun Pharma, offering stockholders $4.10 cash payment.
Why It Matters
Concerns over potential fiduciary breaches in Checkpoint's deal with Sun Pharma could signal risks for shareholders, affecting stock value and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CKPT Stock
What is Checkpoint Therapeutics Inc.'s (CKPT) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Checkpoint Therapeutics Inc. (CKPT) has a median price target of $4.45. The highest price target is $4.80 and the lowest is $4.10.
Is CKPT stock a good investment in 2026?
According to current analyst ratings, CKPT has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CKPT stock?
Wall Street analysts predict CKPT stock could reach $4.45 in the next 12 months. This represents a 4.5% increase from the current price of $4.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Checkpoint Therapeutics Inc.'s business model?
The company generates revenue by developing and commercializing novel cancer therapies that enhance the body's immune response to tumors. Their focus on a diverse pipeline of antibody-based and small molecule therapeutics positions them to address unmet medical needs in oncology, thereby attracting investment for clinical trials and product development.
What is the highest forecasted price for CKPT Checkpoint Therapeutics Inc.?
The highest price target for CKPT is $4.80 from Jason Kolbert at D. Boral Capital, which represents a 12.7% increase from the current price of $4.26.
What is the lowest forecasted price for CKPT Checkpoint Therapeutics Inc.?
The lowest price target for CKPT is $4.10 from Joseph Pantginis at HC Wainwright & Co., which represents a -3.8% decrease from the current price of $4.26.
What is the overall CKPT consensus from analysts for Checkpoint Therapeutics Inc.?
The overall analyst consensus for CKPT is neutral. Out of 7 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $4.45.
How accurate are CKPT stock price projections?
Stock price projections, including those for Checkpoint Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 3:20 AM UTC